Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

382 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.
Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Reuben A, et al. Among authors: hwu p. NPJ Genom Med. 2017;2:10. doi: 10.1038/s41525-017-0013-8. Epub 2017 Apr 7. NPJ Genom Med. 2017. PMID: 28819565 Free PMC article.
Challenges of chemosensitivity testing.
Hwu P, Bedikian AY, Grimm EA. Hwu P, et al. Clin Cancer Res. 2006 Sep 15;12(18):5258-9. doi: 10.1158/1078-0432.CCR-06-1656. Clin Cancer Res. 2006. PMID: 17000655 No abstract available.
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.
Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Frost AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY. Kim KB, et al. Among authors: hwu wj, hwu p. Melanoma Res. 2009 Feb;19(1):42-9. doi: 10.1097/CMR.0b013e328314b84a. Melanoma Res. 2009. PMID: 19430405 Clinical Trial.
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.
Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA. Woodman SE, et al. Among authors: hwu p. Mol Cancer Ther. 2009 Aug;8(8):2079-85. doi: 10.1158/1535-7163.MCT-09-0459. Epub 2009 Aug 11. Mol Cancer Ther. 2009. PMID: 19671763 Free PMC article.
Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals.
Bernatchez C, Zhu K, Li Y, Andersson H, Ionnides C, Fernandez-Vina M, Cano P, Cooper L, Abbruzzese J, Hwu P, Chang DZ, Radvanyi LG. Bernatchez C, et al. Among authors: hwu p. Vaccine. 2011 Apr 5;29(16):3021-30. doi: 10.1016/j.vaccine.2011.01.115. Epub 2011 Feb 12. Vaccine. 2011. PMID: 21320548 Free PMC article.
382 results